Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy

This study is ongoing, but not recruiting participants.

First Received: August 3, 2005 Last Updated: September 11, 2006 History of Changes

Sponsor:	Alberta Cancer Board
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00126815

Purpose

Clinical data (prostate-specific antigen [PSA] response after radiotherapy) are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.

Condition
Prostate Cancer

Study Type:	Observational
Study Design:	Natural History, Cross-Sectional, Defined Population, Retrospective Study
Official Title:	Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

U.S. FDA Resources

Further study details as provided by Alberta Cancer Board:

Estimated Enrollment:	1000
Study Start Date:	February 2004
Estimated Study Completion Date:	July 2005

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Prostate cancer treated with radiotherapy +/- hormones

Exclusion Criteria:

Prostatectomy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00126815

Locations

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2

Sponsors and Collaborators

Alberta Cancer Board

Investigators

Principal Investigator:

Matthew Parliament, MD

Alberta Cancer Board

More Information

No publications provided

Study ID Numbers:	NA-15-0002
Study First Received:	August 3, 2005
Last Updated:	September 11, 2006
ClinicalTrials.gov Identifier:	NCT00126815 History of Changes
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

prostate cancer
prostate specific antigen
radiotherapy
mathematical modeling

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male

Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on November 30, 2009